From Surf Wiki (app.surf) — the open knowledge base
Milbemycin oxime
Chemical compound
Chemical compound
| Drugs.com =
| elimination_half-life =
C32H45NO7 (70%) 555.702 g/mol (70%)
Milbemycin oxime, sold under the brand name Interceptor among others, is a veterinary medication from the group of milbemycins, used as a broad spectrum antiparasitic. It is active against worms (anthelmintic) and mites (miticide).
Mechanism of action
Milbemycins are products of fermentation by Streptomyces species. They have a similar mechanism of action, but a longer half-life than the avermectins. Milbemycin oxime is produced by Streptomyces hygroscopicus aureolacrimosus. It opens glutamate sensitive chloride channels in neurons and myocytes of invertebrates, leading to hyperpolarisation of these cells and blocking of signal transfer.
Uses
Milbemycin oxime is active against a broad spectrum of nematodes. Its miticide spectrum includes Sarcoptes and Demodex. The drug is FDA-approved for prevention of heartworm in dogs and cats, although it is less potent against heartworms than ivermectin.
The substance is often combined with other parasiticides to achieve a broader spectrum of action. Such products include:
- Milbemax and Interceptor Plus (with praziquantel)
- Sentinel Flavor Tabs (with lufenuron)
- Trifexis (with spinosad)
- Nexgard Spectra (with afoxolaner)
The drug has been used in marine reef aquaria to eliminate parasitic Tegastidae arthropod infestations on captive hard coral colonies. This treatment is not selective and will also kill desired arthropods such as shrimps and crabs.
Side effects
The drug is usually tolerated well, but such side effects may occur such as vomiting, phlegming, and glassy eyes.
Society and culture
Legal status
In June 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Bravecto Combiuno chewable tablets intended for dogs. The applicant for this veterinary medicinal product is Intervet International B.V. Bravecto Combiuno is an antiparasitic medicinal product containing fluralaner and milbemycin oxime as active substances. Both substances exert parasiticidal activity by interacting with ligand-gated ion channels in the nervous system of various parasites such as insects, acari and helminths.
References
References
- "Interceptor Flavor Tabs- milbemycin oxime tablet".
- (2012). "An update on the therapy of canine demodicosis". Compendium (Yardley, Pa).
- (2008). "Encyclopedia of Parasitology: A-M". Springer Science & Business Media.
- "NADA 140-915 Interceptor – supplemental approval (September 9, 1996)".
- (2011). "Fundamentals of Ornamental Fish Health". John Wiley & Sons.
- (2011). "Invertebrate Medicine". John Wiley & Sons.
- (13 June 2025). "Bravecto CombiUNO EPAR".
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about Milbemycin oxime — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report